Global

  1. Global—English
  2. 中国—简体中文

Newsroom

Strive to Deliver Breakthroughs

HOME / Newsroom / Press Release
Press Release In the News Image Library Awards & Recognitions
  1. September 13, 2021

    Harbour BioMed Announces Phase I Study Positive Results on Next-Generation Anti-CTLA-4 Antibody HBM4003

    Cambridge, MA, Rotterdam, NL, Suzhou, CN - September 13, 2021   Harbour BioMed (“HBM”, HKEX: 02142) announced positive results from...

    View more
  2. September 01, 2021

    Harbour BioMed Announces IND Approval for Phase II Trial of Anti-FcRn Batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy in China

    Cambridge, MA, Rotterdam, NL, Suzhou, CN - September 1, 2021   Harbour BioMed (“HBM”, HKEX: 02142) today announced that the Center ...

    View more
  3. August 31, 2021

    Harbour BioMed Reports 2021 Interim Results: Product Development Breakthroughs Continue to Unlock Value of Integrated Antibody Discovery Platform

    CAMBRIDGE, Mass.; Suzhou, China; Rotterdam, Netherlands - August 31, 2021   Harbour BioMed (“HBM”, or the "Company”; HKEX: 02...

    View more
  4. July 26, 2021

    HBM Presents Phase I Data on Next-Generation Anti-CTLA-4 Antibody at ESMO Congress 2021

    Cambridge, MA, Rotterdam, NL, Shanghai/Suzhou, CN – July 26, 2021   Harbour BioMed (“HBM”, HKEX: 02142) today announced that t...

    View more
  5. July 21, 2021

    Mount Sinai Entered into Exclusive License Agreement for Neutralizing SARS-CoV-2 Antibody Derived from Harbour BioMed Technology

    Cambridge, MA, Rotterdam, NL, Shanghai/Suzhou, CN – July 21, 2021   Harbour BioMed (“HBM”, HKEX: 02142) today announced that the I...

    View more
  6. July 20, 2021

    Harbour BioMed Appoints Yingying Chen, PhD, as Chief Financial Officer

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – July 20, 2021   Harbour BioMed (“HBM”, HKEX:02142) announced the appointment of Dr. Yin...

    View more
  7. July 16, 2021

    Harbour BioMed Announces Last Patient Dosing of Phase1b/2a Study of Anti-FcRn Batoclimab for Treating Neuromyelitis Optica Spectrum Disorder

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— July 16, 2021      Harbour BioMed (“HBM”, HKEX: 02142) today announced ...

    View more
  8. July 06, 2021

    Harbour BioMed Reports Positive Topline Results from Phase 2 Trial of Batoclimab (HBM9161) in Generalized Myasthenia Gravis

    Cambridge, MA, Rotterdam, NL, Suzhou, CN— July 6, 2021    Both batoclimab 340 mg and 680 mg treatment groups demonstrated rapid, subst...

    View more
  9. June 22, 2021

    Harbour BioMed Appoints Amy Que, PhD, as Chief Technology Officer

    Harbour BioMed (HBM) announced the appointment of Dr. Amy Que as Chief Technology Officer (CTO). Dr. Que will lead the Chemistry, Manufacture and Con...

    View more
  10. June 17, 2021

    Harbour BioMed Announces Dosing of First Patient of Next-Generation Anti-CTLA-4 Antibody in Combination with PD-1 Antibody in Patients with NSCLC

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – June 17, 2021   Harbour BioMed (“HBM”, HKEX: 02142) today announced the dosing of the f...

    View more

Follow
Harbour BioMed
on WeChat

Copyright © 2025 Harbour BioMed. All Rights Reserved
沪公网安备31011502401396号 沪ICP备19015946号-1

FAMILY SITE

中文
ENG